Paul Fanta, MD
Hematology & Oncology · San Diego, CANPI 1467661496
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Trisalus Life Sciences, Inc. accounts for 63.0% of it on its own, with 3 other manufacturers making up the rest. 2023 is the largest year on record at $1,299, more than ten times the $100 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 5 payments — averaging $384.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Trisalus Life Sciences, Inc.$1K
- Deciphera Pharmaceuticals Inc.$525
- Amgen$100
- Intera Oncology, Inc$87
Across 7 payments — averaging $7145.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$50K
- Merck$123
What the payments were for
- Consulting fees$52527%
- Speaking & faculty fees$1,00052%
- Travel & lodging$21211%
- Food & beverage$874%
- Education$1005%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Trisalus Life Sciences, Inc. | 2 | $1,212 |
| Deciphera Pharmaceuticals Inc. | 1 | $525 |
| Amgen | 1 | $100 |
| Intera Oncology, Inc | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRINAV INFUSION SYSTEM$1,212
- QINLOCK$525
How this compares
$1,924 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 20 | $46,190 |
| EliquisApixaban | 57 | $40,294 |
| Everolimus | 13 | $36,493 |
| Imatinib Mesylate | 41 | $28,171 |
| LoperamideLoperamide Hcl | 16 | $359 |
| Ondansetron OdtOndansetron | 16 | $282 |
| Prochlorperazine Maleate | 16 | $206 |
| Oxycodone Hcl | 11 | $98 |
| Furosemide | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in San Diego
- Wendy LevinSan Diego$760K
- Rana McKaySan Diego$530K
- Ezra CohenSan Diego$495K
- Annette von DrygalskiSan Diego$406K
- Lyudmila BazhenovaSan Diego$328K
- Sandip PatelSan Diego$295K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.